LIVER CANCER IN 2019
Joining the dots for better liver cancer treatment
Lo-Kong Chan & Irene Oi-Lin Ng
Nature Reviews Gastroenterology & Hepatology volume 17, pages74–75(2020)Cite this article
397 Accesses
30 Altmetric
Metrics details
In 2019, powerful single-cell analyses were applied to liver cancer biology at an unprecedented level. In parallel with this achievement was the identification of serum α-fetoprotein as a biomarker for patient selection in the use of ramucirumab for liver cancer and that β-catenin activation can distinguish between liver cancer immunotherapy responders and non-responders.
Key advances
Powerful single-cell analyses discover rare cellular sub-populations and complex cell–cell interactions at an unprecedented level, which could help to solve key questions in liver biology and liver cancer2.
The identification of serum α-fetoprotein levels as a biomarker for patient selection in the use of ramucirumab highlights the importance of patient stratification for better treatment outcomes6.
Specific molecular mutations of hepatocellular carcinoma tumours such as β-catenin help to distinguish between immunotherapy responders and non-responders, as well as opening up new avenues for treatments9.
2019年肝癌
齐心协力更好地治疗肝癌